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Gender differences in psychiatric
comorbidity: a population-based study of
40 000 adults with attention deficit
hyperactivity disorder
Solberg BS, Halmøy A, Engeland A, Igland J, Haavik J, Klungsøyr K.
Gender differences in psychiatric comorbidity: a population-based
study of 40 000 adults with attention deficit hyperactivity disorder.
Objective: We aimed at determining whether gender modified
associations between ADHD and psychiatric comorbidities in adults.
Method: We identified adults with ADHD by linking Norwegian
national registries and compared them with the remaining adult
population (born 1967–1997, ADHD and bipolar during 2004–2015,
other psychiatric disorders 2008–2015). Prevalence differences (PDs)
and prevalence ratios (PRs) of psychiatric disorders were determined by
Poisson regression. Interaction by gender was evaluated on additive
(PDs) and multiplicative (PRs) scales. Proportions of psychiatric
disorders attributable to ADHD were calculated.
Results: We identified 40 103 adults with ADHD (44% women) and
1 661 103 adults (49% women) in the remaining population. PDs
associated with ADHD were significantly larger in women than in
men for anxiety, depression, bipolar and personality disorders, for
example depression in women: 24.4 (95% CI, 23.8–24.9) vs. in men:
13.1 (12.8–13.4). PDs were significantly larger in men for schizophrenia
and substance use disorder (SUD), for example SUD in men:
23.0 (22.5–23.5) vs. in women: 13.7 (13.3–14.0). Between 5.6 and 16.5% of
psychiatric disorders in the population were attributable to ADHD.
Conclusion: The association between ADHD and psychiatric
comorbidities differed significantly among men and women. Clinicians
treating adults with ADHD should be aware of these frequent and
gender-specific comorbidities, such that early treatment can be offered.
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Significant outcomes
• Both men and women with ADHD had a 4–9 times higher prevalence of anxiety, depression, bipolar
and personality disorders, schizophrenia and substance use disorder (SUD) than the remaining adult
population.
• Differences in prevalence between ADHD and non-ADHD adults were significantly larger in women
than in men for all psychiatric disorders except schizophrenia and SUD, indicating the larger poten-
tial for introducing preventive measures in women with ADHD.
• A considerable proportion of cases of anxiety, depression, bipolar and personality disorders,
schizophrenia and SUD in the population can be attributed to an underlying comorbid ADHD.
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• This study employed a cross-sectional design, limiting the possibility of making causal conclusions.
• Information on ADHD and psychiatric comorbid disorders was based on data registered in the Nor-
wegian Prescription Database from 2004 to 2015 and in the Norwegian Patient Registry from 2008 to
2015, limiting the study of temporal relations.
• Information on psychiatric comorbid disorders was based on diagnoses registered in secondary
health care, missing comorbidities registered in primary care.
Introduction
Attention deficit hyperactivity disorder (ADHD)
(1, 2) is an impairing and prevalent childhood-
onset disorder that frequently persists into adult-
hood (3–5). Based on an estimated worldwide
prevalence of 2.5% among adults, ADHD affects
millions of individuals across the world and is of
major public health concern (3, 6, 7). The strong
male predominance among children with ADHD
decreases with age; further, comorbidity with
other psychiatric disorders is the rule rather than
the exception, particularly in adults with ADHD
(8–12). It is also known that women with
ADHD are more frequently diagnosed with the
inattentive subtype, as defined in DSM-IV/DSM-
5 (1, 13), with more internalizing comorbid dis-
orders such as depression and anxiety. Women
also report more impairment than men (11, 14–
17), and a study based on self-reports among
adults showed that women with ADHD, more
often than men, reported a history of treatment
for other psychiatric disorders than ADHD (8).
The combined subtype, with more externalizing
symptoms, is more frequent in men (17). This
subtype is more often linked to antisocial per-
sonality disorder and substance use disorder
(SUD) (11, 18).
Several studies have focused on psychiatric
comorbidity in adults with ADHD, for example
anxiety and major depressive disorder (depression)
(3, 11), bipolar disorder (9–11, 19), personality dis-
orders (20, 21), schizophrenia spectrum disorders
(schizophrenia) (19, 22, 23) and SUD (11, 24).
However, existing studies of gender differences in
such comorbidity have shown conflicting results in
adults with ADHD, possibly because of varying
outcome measures, sample characteristics and
methodologies. To gain a better understanding of
gender differences is important in order to be in a
position to provide suitable treatment and preven-
tion strategies for both men and women with
ADHD (18, 25). Few studies have investigated
whether these comorbidities differ between men
and women (26, 27), and large epidemiological
studies of good quality are still lacking (7, 18).
In the present work, we use the term ‘gender’
instead of ‘sex’ because the study concerns adults,
and ‘gender’ is shaped by environment and experi-
ence in addition to the biological characteristics
determined by sex (28).
Aims of the study
We aimed at determining whether gender modified
associations between ADHD and psychiatric
comorbidities. We also aimed at determining the
proportion of psychiatric disorders among men
and women in the population that could be attrib-
uted to a comorbid ADHD.
Method
Study population
We conducted a cross-sectional analysis in a
cohort of adults in Norway, by linking information
from four nationwide, population-based registries:
The Medical Birth Registry of Norway (MBRN),
established in 1967 (29), the Norwegian Prescrip-
tion Database (NorPD) (30), established in 2004,
the Norwegian Patient Registry (NPR) (31), with
data from 2008, and the National Educational
Database (NUDB) from Statistics Norway (32,
33). See Appendix S1 for Supporting Information
and details about the registries. The study included
all individuals born between 1967 and 1997, alive
and resident in Norway at record linkage in 2015
(n = 1 701 206). Record linkage was established
using the national identification number unique to
every Norwegian resident.
The study was approved by the Regional Ethics
Committee in Norway (2011/2272). No informed
consent was required for the analysis of anon-
ymized registry data.
We defined adults with ADHD as those who
had been dispensed their last prescription of
ADHD medication at 18 years of age or more
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during 2004–2015 (NorPD), or with an ADHD
diagnosis registered at 18 years or higher in the
period 2008–2015 (NPR). The ADHD medications
identified were the central stimulants: methylpheni-
date, racaemic amphetamine and dexamphet-
amine, and the non-stimulant drug atomoxetine,
see Appendix S2 for ADHD medication used for
narcolepsy.
The remaining population included all adults
(18 years or older by record linkage) who had nei-
ther been dispensed ADHD medication nor had an
ADHD diagnosis, in the NorPD and NPR respec-
tively. Parents to adults with and without ADHD
were also identified through the MBRN, to evalu-
ate the influence of factors known to be associated
with both ADHD and other psychiatric disorders
(sociodemographic variables, pregnancy-related
risk factors and parental psychiatric disorders).
Measures
We analysed the association between ADHD and
psychiatric disorders among men and women,
ADHD being our ‘exposure’, and evaluated effect
modification by gender. Our main aim was to eval-
uate psychiatric comorbidity in adults with
ADHD, and for this analysis, no confounding
variables are relevant; thus, we only adjusted for
age (birth year; 5-year groups from 1967 to 1997,
with 1967–1973 as the reference period). To evalu-
ate how risk factors for both ADHD and other
psychiatric disorders influenced the prevalence
ratios, we ran two regression models, including the
following covariates that all have been docu-
mented as risk factors for ADHD and psychiatric
disorders (34–41): Model 1: birth year, maternal
marital status (single, married/cohabiting (refer-
ence category), other), maternal age (<20, 20–24,
25–29 (reference value), 30–34, 35–39, 40+) and
paternal age (<20, 20–24, 25–29, 30–34 (reference
value), 35–39, 40–44, 45–49, 50+) at delivery, par-
ent’s highest attained educational level at record
linkage (low (<10 years of education), middle (10–
12 years of education) and high level (>12 years of
education (reference category)), the individual’s
gestational age in weeks (<27, 28–31, 32–34, 35–36,
37–41 (reference value), 42+) and gestational age-
and sex-specific birthweight z-scores (<-2.0; 2.0
to 0.51; 0.5 to 0.5 (reference value); 0.51 to 2.0;
2.01+).
Model 2 further included mothers’ and fathers’
psychiatric diagnoses (yes/no), including ADHD
or any other psychiatric diagnosis from NPR,
2008–2015.
We studied the following major comorbid psy-
chiatric disorders, typically diagnosed in late
adolescence and adulthood, and all registered at
18 years or more: anxiety (ICD-10 codes; F40-
F42), depression (F32-F33), bipolar (F30-F31) and
personality disorders (F60-F61), schizophrenia
(F20-F29) and SUD (F10-F19).
To define bipolar disorder, we used data from
the NorPD in addition to the NPR including indi-
viduals who had been prescribed and dispensed
either lithium during 2004–2015 or anti-epileptic
drugs with mood disorders as the indication during
2008–2015 (indications for psychotropic medica-
tions are only available in the NorPD since 2008).
Statistical analysis
Absolute prevalence differences (PD) of psychiatric
disorders between persons with and without
ADHD among men and women were calculated
using predicted prevalences from a Poisson regres-
sion model with adjustment for birth year (5-year
periods). Significance of interaction by gender on
the additive scale was evaluated using relative
excess risk due to interaction (RERI) (42). While it
has been suggested that effect measures and inter-
actions on the multiplicative scale are better suited
to ‘assess causality’, risk differences and interac-
tions on the additive scale are the most important
to assess public health relevance, indicating which
group may benefit the most from treatment or pre-
ventive measures (42). To examine the association
between ADHD and other psychiatric disorders
on a multiplicative scale, we estimated prevalence
ratios (PR) using Poisson regression with robust
standard errors (43). Significance of interaction by
gender on the multiplicative scale was evaluated by
comparing Poisson regression models with and
without the interaction term (gender x ADHD)
included, as tested by likelihood ratio tests.
Finally, we estimated the proportion of psychiatric
comorbidities attributable to ADHD among men
and women with ADHD (attributable fractions in
the exposed—AFE) and in the population (popu-
lation attributable fractions—PAF) (44). Two-
sided tests with a significance level of 0.05 were
used in all analyses. Analyses were carried out with
PASW Statistics 23 (45) and STATA intercooled
v.14 (46) from 3 January 2016 to 24 July 2017.
Sensitivity analysis
We conducted several sensitivity analyses to test
the robustness of the results, see Appendix S3 in
Supporting Information for details: for all psychi-
atric disorders, we excluded individuals with a
diagnosis of mental retardation, and when analys-
ing prevalences of bipolar disorder, we excluded
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individuals with comorbid schizophrenia. We
repeated analyses including only individuals with
one psychiatric comorbid diagnosis alone. Analy-
ses were also repeated requiring the psychiatric
diagnosis to be registered at least twice in the
NPR. Finally, when adjusting for covariates, we
used multiple imputation with chained equations
(MICE) (47) to evaluate possible biases due to
missing information for gestational age. In the
main analyses, missing values in covariates (6%
for gestational age and birthweight z-scores, other
variables <1%) were handled by listwise deletion.
To impute for missing values in gestational age
and z-scores, we ran sensitivity analyses using
MICE, where the outcome variables, all specified
covariates and also birthweight, maternal preecl-
ampsia and mother’s chronic diseases (yes/no),
were used for information.
Results
Study groups
We identified a total of 40 103 adults with ADHD
(2.4% of the population), 17 815 women (44.4%),
with a total mean age of 31 years in 2015. The
remaining population consisted of 1 661 103
adults, 812 061 women (48.9%) and a mean age
for the total sample of 33 years in 2015. The
male : female ratio in the ADHD group was
1.3 : 1. As shown in Table 1, more mothers of
ADHD adults than remaining mothers had the
lowest educational level (34.9% vs. 26.2%) and
were single when giving birth (16.8% vs. 9.2%).
Also, parents of ADHD adults had significantly
more psychiatric disorders than parents of the
remaining population (mothers: 27.3 vs. 13.4%;
fathers: 17.3 vs. 9.9%).










No. (%) 40 103 (2.4) 1 661 103 (97.6) 17 815 (44.4) 22 288 (55.6)
Gender
Women 17 815 (44.4) 812 061 (48.9)
Men 22 288 (55.6) 849 042 (51.1)
M:F ratio 1.25 1.05
Mean age in 2015 (years) (SD) P < 0.001* P < 0.001**
31.2 (8.3) 33.1 (9.3) 31.4 (8.4) 31.0 (8.2)
Gestational age (weeks) P < 0.001* P < 0.001**
<27 113 (0.3) 2464 (0.2) 43 (0.3) 70 (0.3)
28–31 283 (0.8) 7835 (0.5) 101 (0.6) 182 (0.9)
32–34 677 (1.9) 22 239 (1.4) 270 (1.7) 407 (2.0)
35–36 1313 (3.6) 49 624 (3.2) 532 (3.3) 781 (3.8)
37–41 28 552 (77.9) 1 250 422 (80.3) 12 660 (77.8) 15 892 (78.1)
42+ 5701 (15.6) 223 779 (14.4) 2661 (16.4) 3040 (14.9)
Missing 3464 (8.6) 104 740 (6.3) 1548 (8.7) 1916 (8.6)
Maternal marital status P < 0.001* P = 0.9**
Married/cohabitant 32 342 (80.9) 1 489 193 (89.8) 14 354 (80.8) 17 988 (80.9)
Single 6708 (16.8) 152 884 (9.2) 2996 (16.9) 3712 (16.7)
Other 944 (2.4) 16 250 (1.0) 419 (2.4) 525 (2.4)
Missing 109 (0.3) 2776 (0.2) 46 (0.3) 63 (0.3)
Maternal educational status P < 0.001* P = 0.8**
Low 13 892 (34.9) 432 778 (26.2) 6197 (35.0) 7695 (34.7)
Middle 17 061 (42.8) 771 795 (46.7) 7629 (43.1) 9432 (42.6)
High 8903 (22.3) 449 945 (27.2) 3877 (21.2) 5026 (22.7)
Missing 247 (0.6) 6585 (0.4) 112 (0.6) 135 (0.6)
Paternal educational status P < 0.001* P = 0.006**
Low 12 889 (33.0) 382 793 (23.4) 5695 (32.8) 7194 (33.2)
Middle 19 320 (49.5) 838 027 (51.2) 8746 (50.4) 10 574 (48.8)
High 6827 (17.5) 416 636 (25.4) 2914 (16.8) 3913 (18.1)
Missing 1067 (2.7) 23 647 (1.4) 460 (2.6) 607 (2.7)
Maternal psychiatric disorder P < 0.001* P = 0.99**
None 29 149 (72.7) 1 437 851 (86.6) 12 977 (72.8) 16 172 (72.6)
Any, including ADHD 10 953 (27.3) 223 216 (13.4) 4838 (27.2) 6115 (27.4)
Paternal psychiatric disorder P < 0.001* P = 0.06**
None 32 667 (82.7) 1 485 656 (90.1) 14 609 (83.2) 18 058 (82.2)
Any, including ADHD 6848 (17.3) 162 779 (9.9) 2941 (16.8) 3907 (17.8)
*P-value (Pearson’s chi-square test and t-test for equality of means) for the difference in ADHD total relative to the comparison population.
**P-value (Pearson’s chi-square test and t-test for equality of means) for the difference in men with ADHD vs. women with ADHD.
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Association between ADHD and psychiatric comorbidities in men
and women
Adults with ADHD had a much higher prevalence
of additional psychiatric disorders compared to the
remaining population, as shown in Fig. 1. As many
as 53.5% of women and 48.5% of men with ADHD
had one or more of the six studied psychiatric
comorbidities, compared to 13.7% of women and
9.1% of men in the remaining population. Women
with ADHD had the highest prevalence of all disor-
ders except schizophrenia and SUD (Fig. 1).
Evaluated on an absolute scale, the prevalence
differences (PD) between adults with and without
ADHD were statistically significant for all the psy-
chiatric disorders and ranged from 2.1% (95% CI
2.0–2.3) for schizophrenia to 24.4% (23.8–24.9) for
depression, both in women, see Table 2.
Evaluated on a multiplicative scale, adult ADHD
was most closely associated with bipolar disorder,
personality disorders and SUD, with PR estimates
ranging from 7.2 (95% CI, 7.0–7.5) for SUD in
women to 8.9 (8.5–9.3) for bipolar and personality
disorders in men. Associations with anxiety, depres-
sion and schizophrenia were weaker, though still
strong, with a four to five times higher prevalence of
these disorders in both men and women with
ADHD than those without, see Table 3.
Interaction by gender
Interaction by gender was tested both on the addi-
tive and the multiplicative scales, see Tables 2 and
3. When testing for interaction by gender on an
additive scale, the PDs were significantly larger in
women than in men for all psychiatric comorbidi-
ties except schizophrenia and SUD, where the PDs
were larger in men. On the multiplicative scale, the
associations with ADHD were significantly stron-
ger in men than in women for anxiety, depression,
bipolar and personality disorders, see Table 3.
Attributable proportions
A large proportion of psychiatric disorders among
adults with ADHD could be attributed to their
existing ADHD condition, with AFE ranging from
72.9% to 87.5% in women and 79.5% to 88.8% in
men, see Table 3. The proportions of psychiatric
disorders in the adult population that could be
attributed to a comorbid ADHD were also high,
with PAF ranging from 5.6% to 13.0% in women
and from 8.9% to 16.5% in men.
Sensitivity analysis
The results of the sensitivity analyses are shown in
Supporting Information, Tables S1–S3. All sensi-
tivity analyses were compatible with the results of
the main analyses.
Discussion
This is the first large population-based study per-
formed on adults clinically diagnosed with ADHD
to evaluate gender differences in major psychiatric



































Fig. 1. Adjusted* prevalences of psychiatric disorders in men and women with and without ADHD. *Prevalences was adjusted for
birth year, 5-year groups, from 1967 to 1997, with 1967–1973 as the reference. SUD, Substance use disorder.
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Table 2. Prevalence differences in psychiatric disorders in men and women with and without ADHD. Effect modification by gender evaluated on an additive scale
Psychiatric disorders (ICD-10)
Crude prevalences, No. (%) Prevalence, % (95% CI)*
Additive effect modification†
ADHD Non-ADHD ADHD Non-ADHD PD‡ (95% CI) RERI§ (95% CI)
Anxiety disorders (F40–42)
Women 4676 (26.3) 54 479 (6.7) 28.7 (28.2–29.3) 6.6 (6.6–6.7) 22.1 (21.6–22.6) 1.4 (1.2–1.7)*¶
Men 4054 (18.2) 28 364 (3.3) 14.8 (14.5–15.1) 3.4 (3.4–3.5) 11.4 (11.1–11.7)
Bipolar disorder (F30–31 or medication)k
Women 2290 (12.9) 13 183 (1.6) 13.5 (13.1–13.9) 1.6 (1.6–1.6) 11.9 (11.5–12.3) 3.4 (2.7–4.0)*
Men 1981 (8.9) 9009 (1.1) 8.9 (8.7–9.2) 1.1 (1.0–1.1) 7.9 (7.6–8.1)
Major depressive disorder (F32–33)
Women 5138 (28.8) 61 880 (7.6) 31.9 (31.4–32.5) 7.5 (7.5–7.6) 24.4 (23.8–24.9) 1.3 (1.1–1.5)*
Men 4516 (20.3) 33 733 (4.0) 17.1 (16.8–17.5) 4.1 (4.0–4.1) 13.1 (12.8–13.4)
Personality disorder (F60–61)
Women 2428 (13.6) 14 079 (1.7) 14.0 (13.6–14.5) 1.7 (1.7–1.7) 12.3 (11.9–12.7) 3.8 (3.2–4.4)*
Men 2030 (9.1) 8909 (1.1) 8.7 (8.4–8.9) 1.1 (1.0–1.1) 7.6 (7.3–7.9)
Schizophrenia spectrum disorder (F20–29)
Women 444 (2.5) 4621 (0.6) 2.7 (2.5–2.8) 0.6 (0.5–0.6) 2.1 (2.0–2.3) 1.8 (2.2; 1.3)*
Men 928 (4.2) 7352 (0.9) 4.1 (3.9–4.3) 0.9 (0.8–0.9) 3.3 (3.0–3.5)
Substance use disorder (F10–19)
Women 2878 (16.2) 17 200 (2.1) 15.8 (15.4–16.1) 2.1 (2.1–2.1) 13.7 (13.3–14.0) 2.9 (3.1; 2.7)*
Men 6135 (27.5) 30 233 (3.6) 26.6 (26.1–27.1) 3.6 (3.5–3.6) 23.0 (22.5–23.5)
ICD-10, International Statistical Classification of Diseases and Related Health Problems 10th Revision, World Health Organization; CI, confidence interval; PD, prevalence differ-
ence; RERI, relative excess in risk due to interaction.
*Prevalence adjusted for birth year (5-year groups, from 1967 to 1997, with 1967–1973 as the reference period).
†Female gender as reference group.
‡Prevalence Difference (PD) between adults with and without ADHD, adjusted for birth year as above.
§Relative Excess in Risk due to Interaction (RERI) adjusted for birth year as above.
¶P-value of interaction on an additive scale, all P < 0.001.
kMedication: lithium during 2004–2015 or anti-epileptic drugs with mood disorders as the indication during 2008–2015.
Table 3. Prevalence ratios of psychiatric disorders men and women with and without ADHD. Effect modification by gender evaluated on a multiplicative scale
Psychiatric disorders
Crude prevalences, No. (%) Prevalence ratios (95% CI) Attributable fraction (95% CI)
ADHD Non-ADHD Crude† Model 1‡ Model 2§ AFE¶ PAFk
Anxiety Disorders P < 0.001** P < 0.001 P < 0.001 ††
Women 4676 (26.3) 54 479 (6.7) 3.7 (3.7–3.8) 3.6 (3.5–3.7) 3.4 (3.3–3.5) 73.3 (72.6–74.0) 5.8 (5.6–6.0)
Men 4054 (18.2) 28 364 (3.3) 5.3 (5.2–5.5) 5.1 (4.9–5.2) 4.7 (4.5–4.8) 81.2 (80.6–81.7) 10.2 (9.8–10.5)
Bipolar Disorder P = 0.03 P = 0.03 P = 0.07
Women 2290 (12.9) 13 183 (1.6) 8.0 (7.7–8.3) 7.8 (7.5–8.2) 7.2 (6.8–7.5) 87.5 (87.0–88.0) 13.0 (12.4–13.5)
Men 1981 (8.9) 9009 (1.1) 8.9 (8.5–9.3) 8.9 (8.5–9.4) 8.1 (7.7–8.5) 88.8 (88.2–89.3) 16.0 (15.3–16.7)
Major depressive disorder P < 0.001 P < 0.001 P < 0.001
Women 5138 (28.8) 61 880 (7.6) 3.7 (3.6–3.8) 3.6 (3.5–3.7) 3.3 (3.2–3.4) 72.9 (72.2–73.5) 5.6 (5.4–5.8)
Men 4516 (20.3) 33 733 (4.0) 5.1 (5.0–5.3) 4.9 (4.8–5.0) 4.5 (4.4–4.6) 80.5 (79.9–81.0) 9.5 (9.2–9.8)
Personality disorder P = 0.001 P = 0.008 P = 0.02
Women 2428 (13.6) 14 079 (1.7) 7.7 (7.3–8.0) 7.1 (6.8–7.4) 6.5 (6.2–6.8) 86.9 (86.4–87.5) 12.8 (12.3–13.3)
Men 2030 (9.1) 8909 (1.1) 8.9 (8.5–9.3) 8.1 (7.7–8.5) 7.3 (6.9–7.7) 88.8 (88.2–89.3) 16.5 (15.8–17.2)
Schizophrenia spectrum disorder P = 0.08 P = 0.07 P = 0.1
Women 444 (2.5) 4621 (0.6) 4.5 (4.1–4.9) 4.5 (4.1–5.0) 4.1 (3.7–4.6) 77.7 (75.4–79.7) 6.8 (6.0–7.6)
Men 928 (4.2) 7352 (0.9) 4.9 (4.6–5.2) 4.8 (4.5–5.2) 4.3 (4.0–4.7) 79.5 (78.0–80.8) 8.9 (8.2–9.6)
Substance use disorder P = 0.4 P = 0.7 P = 0.98
Women 2878 (16.2) 17 200 (2.1) 7.2 (7.0–7.5) 6.3 (6.1–6.6) 5.8 (5.6–6.0) 86.2 (85.7–86.7) 12.4 (11.9–12.8)
Men 6135 (27.5) 30 233 (3.6) 7.6 (7.4–7.8) 6.6 (6.5–6.8) 6.1 (6.0–6.3) 86.8 (86.5–87.1) 14.6 (14.3–15.0)
CI, Confidence interval; ADHD, adults with ADHD; non-ADHD, remaining population without ADHD; AFE, attributable fraction among the exposed; PAF, population attributable fraction.
†Adjusted for birth year (5-year groups from 1967 to 1997, with 1967–1973 as the reference period).
‡Model 1: Adjusted for birth year, maternal marital status (single, married/cohabiting (reference category), other), maternal and paternal education (low (<10 years of education),
middle (10–12 years of education and high level (>12 years of education (reference category)), maternal age (<20, 20–24, 25–29 (reference value), 30–34, 35–39, 40+) and
paternal age (<20, 20–24, 25–29, 30–34 (reference value), 35–39, 40–44, 45–49, 50+) at delivery, gestational age (<27, 28–31, 32–34, 35–36, 37–41 (reference value), 42+),
gestational age and sex-specific birthweight z-scores (<2.0; 2.0 to 0.51; 0.5 to 0.5 (reference value); 0.51–2.0; 2.01+).
§Model 2: As in Model 1 and additionally adjusted for maternal and paternal psychiatric disorders (yes/no).
¶Attributable fraction among the exposed (AFE) (%) (=ADHD population), based on crude model.
kPopulation attributable fraction (PAF) (%), based on crude model.
**P-value of the interaction between ADHD and sex on a multiplicative scale.
††Statistical significant difference between men and women with ADHD based on non-overlapping 95% confidence intervals.
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on both multiplicative and additive scales. Both
men and women with ADHD had 4–9 times higher
prevalences of all the studied psychiatric disorders
than the remaining adult population. However, on
an absolute scale, differences in prevalence between
ADHD and non-ADHD adults were significantly
larger in women than in men for all psychiatric dis-
orders except schizophrenia and SUD, indicating
the larger potential for preventive measures in
women with ADHD. The proportions of psychi-
atric disorders in the population attributable to a
comorbid ADHD were large for both genders.
In line with previous studies in the literature, we
found higher prevalences of all the studied comor-
bidities in adults with ADHD than in those with-
out (3, 10). However, few previous studies have
evaluated gender differences in comorbidity among
adults with ADHD, and results from existing stud-
ies are conflicting. A study of 219 clinically diag-
nosed adults with ADHD, including 37.4%
women, found no gender difference in risk of anxi-
ety, bipolar disorder, depression, SUD and antiso-
cial personality disorder, but that study was in all
likelihood underpowered (11). One of the largest
population-based studies until now, a twin-study
using self-reported symptom scores for both
ADHD and other psychiatric disorders, studied
anxiety, bipolar disorder, depression and alcohol
dependence. Similar relative risk estimates for anx-
iety and bipolar disorder as in our study were
reported, but gender differences were not found
(26). In another recent twin-study based on self-
reported symptom scores, a high risk of comorbid
SUD in adults with ADHD was reported, but this
did not report finding any gender differences (24).
Among studies showing high risk of comorbid
bipolar disorder, one was large and population-
based, but involved both children and adults (19);
another study was small with low female represen-
tation (11). Both studies considered gender differ-
ences, but none were found. A large Swedish study
analysed risk of comorbid schizophrenia, but did
not focus on adults and did not evaluate gender
differences (19). A smaller Danish study found the
same relative risk of comorbid psychosis as
observed here, but in adults diagnosed with
ADHD as children. The study only included a
small proportion of women, and an evaluation of
gender differences was thus not possible (22). A
large study from Taiwan with over 70 000 individ-
uals with ADHD diagnosed in childhood reported
a five times higher risk of developing some form of
psychotic disorder. The male proportion was 80%,
and mean age at diagnosed psychosis was only
15 years. An increased risk for psychosis in women
with ADHD was, however, found (23). The
number of studies on ADHD and different person-
ality disorders is smaller and mostly performed on
young adults and adolescents, where ADHD was
diagnosed in childhood. Hazard ratios of 5.8 for
personality disorders ‘not specified’ and 3.1 for
antisocial personality disorder have been reported
without specification of gender (21, 48).
Most previous studies have their limitations:
they have either relied on self-reported diagnosis of
ADHD diagnosis or screening questionnaires,
many studies are small, and most of them have a
low proportion of females or include individuals
younger than 18 years at the time of comorbid
diagnosis. Few studies have been population-based
or focused specifically on gender differences in risk
of comorbidities in adults.
In a recent narrative meta-analysis of gender dif-
ferences in adult ADHD, Williamson and John-
ston found that only three of 11 studies included
appropriate comparison groups (18). However, the
most important difference, and novelty of the pre-
sent study, is that we tested for interaction by gen-
der on an additive scale, thus using the prevalence
differences to estimate the prevention potential.
We also calculated the proportion of major psychi-
atric disorders that could be attributed to ADHD
in the adult population.
Testing for interaction on the additive scale is
informative for clinical and public health ques-
tions, because it may indicate which subgroups
need to be prioritized such that preventive mea-
sures and interventions can be introduced (42). We
found that differences in prevalences of anxiety,
depression, bipolar and personality disorders
between adults with and without ADHD were sig-
nificantly larger for women than for men, while the
opposite was true for SUD and schizophrenia. Pre-
vious investigations have failed to show these gen-
der differences in psychiatric comorbidities, and
none have evaluated interactions on an additive
scale. Women with ADHD have been shown to
report more symptoms and impairments resulting
from their condition than men, thus possibly pre-
disposing them to a higher level of psychiatric
comorbidity (11, 14–16, 49). Our results show that
there is a relatively higher increase in prevalence of
most psychiatric comorbidities associated with
ADHD in women with ADHD fitting this. Detect-
ing and treating ADHD in girls and women may
prove to be an important preventive measure in
order to reduce the risk of future psychiatric
comorbidity. Paying more attention towards girls
and women with ADHD, who have less hyperac-
tivity and therefore may go undiagnosed during
childhood years, may thus be warranted, both
among clinicians and researchers (25). The larger
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increase in SUD and schizophrenia associated with
ADHD in men is also of importance, and clini-
cians treating adults with ADHD should be aware
of the gender-specific comorbidities described in
our study, both with respect to detection and the
offer of early treatment following diagnosis.
The larger increase in prevalence of schizophre-
nia associated with ADHD in men might be
related to the larger increase in prevalence of SUD,
also found in men. Both having ADHD (10, 24)
and being a male (50, 51) increase the risk of SUD,
and SUD itself may increase the risk of psychosis
(52). To test this hypothesis, we excluded all indi-
viduals with SUD in the study population
(n = 62 434) and reran the PD analyses for
schizophrenia. The PDs of schizophrenia in
women with and without ADHD changed from
2.1 (95% CI, 2.1–2.1) to 1.1 (1.0–1.3) and in men
from 3.3 (3.0–3.5) to 1.4 (1.2–1.6). The gender dif-
ference was still statistically significant (RERI
0.66, 95% CI, 1.3 – 0.07). We therefore
believe that the increased risk of schizophrenia in
men with ADHD may be partly, although not fully
explained, by a comorbid SUD. The apparent
increased vulnerability to schizophrenia in men
with ADHD could be of clinical importance. In
contrast, when excluding all cases with SUD, the
PD for women was no longer significant when
compared to women without ADHD.
The relatively increased risk of anxiety and
depression in men with ADHD on the multiplica-
tive scale may partly be explained by the low
prevalence of these disorders in men without
ADHD, who generally have lower health-seeking
behaviour (53). Men with ADHD are already in
contact with the health services and may therefore
get these comorbid disorders diagnosed more
easily than their non-ADHD counterparts.
Although both men and women with ADHD are
in contact with the health services, women, inde-
pendently of ADHD, are generally in closer con-
tact with the health services than men, due to, for
example, maternal health issues (fertility regula-
tion, pregnancy and childbirth) (54). This may
partly explain why disorders such as depression
and anxiety are more easily detected in women
than in men in the general population (50, 55).
The gender-specific pattern of psychiatric disor-
ders that we find among adults with ADHD in our
study is similar to the pattern found in the general
population (50, 51, 56). The absolute prevalence
rates are, however, much higher for both men and
women with ADHD, as shown in Fig. 1. Although
the presence of ADHD enhances the trend among
men and women in the general population, it is evi-
dent that the magnitude of this enhancement
differs between men and women and is also depen-
dent on the specific disorder.
To evaluate how associations between ADHD
and psychiatric comorbidities were influenced by
common risk factors for both ADHD and other
psychiatric disorders, we adjusted for socioeco-
nomic and perinatal risk factors (Model 1). This
hardly changed the PR estimates. When also
including psychiatric disorders of the parents in
the model (Model 2), the estimates were slightly
attenuated, suggesting that genetic predisposition
or problems linked to having parents suffering
from psychiatric diseases are important, see
Table 3. This calls for increased attention regard-
ing children of parents being treated for psychiatric
disorders.
Strengths and limitations
Our study has several strengths. We used data
from nationwide health registries of good quality
and with mandatory, prospective reporting, mini-
mizing selection bias and loss to follow-up and
eliminating recall bias. Bipolar disorder and
schizophrenia registration in the NPR have been
validated with good results (31). Due to the large
study population with almost 45% women with
ADHD, we could evaluate less prevalent disorders,
such as schizophrenia, and compare psychiatric
comorbidity in men and women with representa-
tive numbers in both groups. We had prospectively
registered data on perinatal factors (birthweight
and gestational age) for the whole study popula-
tion, and we had information on psychiatric diag-
noses, including ADHD, for the parents.
Therefore, we could adjust for these covariates to
evaluate whether these risk factors explained the
increased prevalence of psychiatric comorbidities
in adults with ADHD.
Unlike some other large Scandinavian popula-
tion-based studies, we did not use ADHD symp-
tom ratings or self-reports to define ADHD.
ADHD medication is restricted in Norway, and
medical treatment in adults is initiated only after
thorough assessment by a specialist in psychology
or psychiatry. Therefore, we believe that a pre-
scribed and dispensed prescription of ADHD med-
ication is a good proxy for a clinical ADHD
diagnosis. Calculating PDs and testing for interac-
tion by gender on the additive scale give relevant
information concerning which comorbid diagnoses
clinicians should be especially aware of when
following men and women with ADHD. Our
estimates of attributable risk of comorbid disor-
ders in men and women with ADHD underscore
the gender-specific prevention potential.
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We are aware that our study also has some limi-
tations: analyses were cross-sectional and based on
data registered in the NorPD from 2004–15 and in
the NPR from 2008–15, limiting the study of tem-
poral relations. However, as ADHD is defined as a
neuropsychiatric disorder with onset in childhood,
we may assume that ADHD was present before
the comorbid psychiatric disorders, which all are
typically diagnosed in late adolescence and adult-
hood. Since the NorPD was established in 2004,
adults diagnosed and treated for ADHD only
before 2004 and not after will be undetected. How-
ever, ADHD was not understood as a disorder of
adulthood before the late 1990s, and during 1997–
2005, adults in Norway were only allowed to
receive medical treatment with central stimulants
after a thorough evaluation by one of three regio-
nal diagnostic committees (8). Further, some
ADHD patients will not receive medication
because of contraindications or other causes; these
patients are identified in the NPR, but only from
2008 and onwards. During 2008–2015, a total of
9346 (23.3%) adults with ADHD were registered
with ADHD in the NPR without receiving medica-
tion.
The NPR was the data source for defining psy-
chiatric comorbidities. In Norway, many psychi-
atric patients are followed in primary health care
after diagnosis, and treatment is established in sec-
ondary care, for example patients with bipolar dis-
order who are stable on medication. A recent
study from Sweden reported that almost 80% of
the most common mental disorders were treated in
primary care (57). For bipolar disorder, we there-
fore used the NorPD as an additional data source.
It is likely that patients with the more severe disor-
ders such as schizophrenia (31) and severe person-
ality disorders will likely have some contact with
specialist health care throughout life and should
therefore be captured by the NPR.
As discussed above, it may be argued that adults
with ADHD could more easily be diagnosed with
other psychiatric disorders because they are
already in contact with the health services (55).
This may be true, especially for depression and
anxiety in men, who in general have little contact
with the health service before old-age (54). How-
ever, adults with bipolar disorder, schizophrenia,
personality disorders and SUD are likely to be
referred to secondary health care also in the non-
ADHD population.
To conclude, a large proportion of both men
and women with ADHD have comorbid psychi-
atric disorders, and a considerable proportion of
anxiety, bipolar disorder, depression, schizophre-
nia, SUD and personality disorders in the
population can be attributed to an underlying
comorbid ADHD. The differences in prevalence of
anxiety, depression, bipolar and personality disor-
ders in adults with and without ADHD are larger
for women than for men. Clinicians treating
women with ADHD should be aware of these
comorbidities, to both detect the conditions and
offer early treatment if diagnosed. Similarly, the
possibility of a comorbid SUD or schizophrenia
spectrum disorder is particularly relevant when
treating men with ADHD. Importantly, clinicians
should also be aware of a possible underlying
ADHD when adults present with symptoms of
other psychiatric disorders. Identifying children
and adolescents with ADHD at earlier stages may
be an important preventive measure to reduce the
risk of future psychiatric comorbidity. This may be
particularly important in girls and women with
ADHD, who often have a lower degree of hyperac-
tivity and are therefore at an increased risk of
being undiagnosed in childhood, with a higher risk
of developing other psychiatric disorders as a pos-
sible consequence.
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